This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Calendar: More Key Clinical Trial Dates

As promised, I'm back this week with another clinical trials list covering experimental drugs currently undergoing testing in phase II and phase III studies by drug and biotech companies.

This list serves as a companion to my June 10 column.

Unlike U.S. Food and Drug Administration drug approvals, which are more precisely timed, the release dates for data from clinical trials is bit fuzzier, so the timelines here are culled from company guidance when possible.

The working list of clinical trials expected to complete in 2009 is fairly long, so expect more information on clinical trials to watch in the coming weeks.

I put this calendar together using company reports, sell-side research and the BioMedTracker service from Sagient Research -- a subscription-based tool for keeping track of biotech and drug catalysts.

Company: GTx (GTXI)
Drug/indication: Acapodene for precancerous prostate lesions (high-grade PIN)
Clinical trial event: phase III top-line results
Timing: late summer

The phase III study will determine if treatment with Acapodene can reduce the occurrence of prostate cancer in men with high-grade PIN -- precancerous prostate lesions that place men at higher risk for prostate cancer.

Company: Incyte (INCY)
Drug/indication: INCB18424 for psoriasis
Clinical trial event: phase II results
Timing: late summer

Incyte recently announced agreement with the FDA on endpoints for a phase III study of oral '8424 in patients with myelofibrosis. But the company is also developing a topical form of the drug for the treatment of mild to moderate psoriasis.

Company: Jazz Pharmaceuticals (JAZZ)
Drug/indication: JZP-6 for fibromyalgia
Clinical trial event: phase III top-line results
Timing: mid-2009
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PARD $0.08 0.00%
BMY $68.08 0.38%
CELG $112.35 -0.28%
GTXI $0.99 5.24%
OREX $2.33 -2.51%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs